Spots Global Cancer Trial Database for relapsed small cell lung cancer
Every month we try and update this database with for relapsed small cell lung cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | NCT05153239 | Relapsed Small ... | Irinotecan Lurbinectedin Irinotecan Topotecan Lurbinectedin | 18 Years - | PharmaMar | |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | NCT05153239 | Relapsed Small ... | Irinotecan Lurbinectedin Irinotecan Topotecan Lurbinectedin | 18 Years - | PharmaMar | |
| Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | NCT06128837 | Relapsed Small ... | Irinotecan hydr... Topotecan | 18 Years - | Luye Pharma Group Ltd. | |
| AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | NCT02511795 | Refractory Soli... Relapsed Small ... | AZD1775 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | NCT06128837 | Relapsed Small ... | Irinotecan hydr... Topotecan | 18 Years - | Luye Pharma Group Ltd. | |
| Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | NCT04610658 | Small-cell Lung... Relapsed Small ... Recurrent Small... | Nivolumab Ipilimumab Lurbinectedin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT03334487 | Small Cell Lung... | Dexamethasone Rovalpituzumab ... | 18 Years - | AbbVie | |
| Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects | NCT04939662 | Lung Cancer | Olaparib+Bevaci... | 19 Years - | Samsung Medical Center | |
| Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | NCT03406715 | Small Cell Lung... Lung Cancer Relapsed Small ... | Nivolumab Ipilimumab Dendritic Cell ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | NCT02511795 | Refractory Soli... Relapsed Small ... | AZD1775 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients | NCT04421352 | Relapsed Small ... | CS1001 | 18 Years - 75 Years | CStone Pharmaceuticals | |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | NCT05153239 | Relapsed Small ... | Irinotecan Lurbinectedin Irinotecan Topotecan Lurbinectedin | 18 Years - | PharmaMar | |
| Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC | NCT04610658 | Small-cell Lung... Relapsed Small ... Recurrent Small... | Nivolumab Ipilimumab Lurbinectedin | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
